Abstract
Achievements in primary open-angle glaucoma (POAG) treatment unfortunately do not ensure an adequate neuroprotective effect in monotherapy of the disease that is why a search for effective and affordable neuroprotectors continues. The aim of the study was to assess the neuroprotective effect of herbal medicinal product “Tanakan” in treatment of POAG patients with normalized intraocular pressure. Methods. A complex clinical and morphological randomized crossover study. Thirty patients (57 eyes) with established stage I-II POAG were examined. Results. During the period from no treatment, up to 3 and 6 months from the treatment start, a reliable increase of the Jantch index (Jantch, 1958) was noted. A positive trend in values of electrophysiological indices was revealed: macular ERG (MERG) a-wave amplitude, and rhythmic ERG (RERG) a-wave amplitude increased. A positive dynamics was found when performing vacuum tests with dosated intraocular pressure (IOP) increase: p-100 complex amplitude increase without its latency changes, as a result of vacuum-compression test with visual evoked cortical potentials (VCT with VECP); with laser confocal tomography, a decrease of maximal optic disc excavation depth at maximal vacuum load was established. Conclusions. An increase of functional visual analyzer performance capabilities at the 1st, 2nd and 3rd neurons level without any changes in optic disc morphometric parameters could be qualified as a neuroprotective effect of the treatment. The increase in the Jantch index, as well as the decrease of maximal optic disc excavation depth as a result of artificial IOP increase may be qualified as an increase in optic nerve tolerance. Tanakan could be used complementary, as a neuroprotector, in combined therapy in stage I-II POAG patients at normalized IOP as long-term (up to 6 months) therapy courses.
Highlights
8. Динамика изменений амплитуды комплекса р-100 через 3 и 6 месяцев от начала приёма препарата по данным ВКП с ЗВКП, р < 0,01
3) Нарастание реографического коэффициента по Янтчу в течение всего срока наблюдения, а также тенденция к уменьшению максимальной глубины экскавации диска зрительного нерва в ответ на искусственное повышение ВГД может быть расценено как увеличение устойчивости зрительного нерва при дополнительном лечении «Танаканом» у больных с ранними (I–II) стадиями ПОУГ. 4) Препарат Танакан может быть использован в комплексном лечении ПОУГ I–II стадий у больных с нормализованным офтальмотонусом как дополнительный нейропротектор в комбинированной терапии
The aim of the study was to assess the neuroprotective effect of herbal medicinal product “Tanakan” in treatment of primary open-angle glaucoma (POAG) patients with normalized intraocular pressure
Summary
8. Динамика изменений амплитуды комплекса р-100 через 3 и 6 месяцев от начала приёма препарата по данным ВКП с ЗВКП, р < 0,01 9. Динамика изменений латентности комплекса р-100 через 3 и 6 месяцев от начала приёма препарата по данным ВКП с ЗВКП Исследования авторефрактометрии, визометрии и темновой адаптометрии до и на фоне приёма препарата показали статистически не достоверные изменения, и их результаты были расценены как стабильные.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
